NephroGenex Inc

NephroGenex — Investor Presentation (February 2015)

30 slides from NephroGenex's investor presentation, Feb 24, 2015

  1. Slide 1: Corporate Presentation February 2015

    Corporate Presentation February 2015

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements This presentation includes statements that are, or may be deemed, ‘‘forward-looking statements.’’ In some cases, these forward- looking statements can be identified by the use of forward-looking terminology, including the terms “believes,” “estimates,” “anticipates,” “expe

  3. Slide 3: Corporate Overview

    Corporate Overview Late-stage company developing therapies that target the underlying cause of kidney disease  Oral Pyridorin (Phase 3) – an inhibitor & scavenger of oxidative chemistries to slow progression of diabetic nephropathy (DN) – chronic  I.V. Pyridorin (Preclinical) – to treat acute kidn

  4. Slide 4: The NephroGenex Team

    The NephroGenex Team Member Affiliation, Position Pierre Legault, CEO Sanofi-Aventis, President Worldwide Dermatology Eckerd, President Rite Aid, CAO OSI Pharmaceuticals, CFO Prosidion Ltd, CEO Board Member, NPS, Regado Biosciences, Cyclacel, Forest Labs J. Wesley Fox, Ph.D., President & CSO BioStra

  5. Slide 5: Financial Overview: Cash and Capital Structure

    Cash  As of September 30, 2014 approximately $26.6 million in cash, cash equivalents and investments  $12 million term loan facility with East West Bank ($7M in November 2014 & $5M in 2015 after certain conditions are met) maturing in October 2018  Sufficient cash balance to finance operations in

  6. Slide 6: The NephroGenex Pipeline

    The NephroGenex Pipeline 6 Clinical Program / Indication Preclinical Phase 1 Phase 2 Phase 3 Worldwide Commercial Rights ORAL PYRIDORIN ® Diabetic Nephropathy I.V. PYRIDORIN ® Acute Kidney Injury Chronic oral bid 300 mg tablet targets pathogenic oxidative chemistries 2015 I.V. formulation for hospit

  7. Slide 7: Pathophysiology of Diabetic Nephropathy (DN)

    Pathophysiology of Diabetic Nephropathy (DN)  Pyridorin targets pathogenic oxidative chemistries and AGE formation  Pyridorin is an inhibitor and scavenger of these toxic carbonyls and AGEs (AGEs are recognized causative and promoting factors in DN)  DN is the leading cause of dialysis and chroni

  8. Slide 8: Pyridorin Mechanism of Action

    AGEs bind to receptors on the cells that comprise the glomerulus inducing pathological changes which adversely affect their filtration function. AGEs do not form and protein does not bind to receptors on the cells that comprise the glomerulus and therefore no pathology is induced. Pyridorin inhibits

  9. Slide 9: Promising early results for Intravenous Pyridorin

    Promising early results for Intravenous Pyridorin  Pyridorin targets specific pathogenic oxidative chemistries that emerge in diabetes  These pathogenic oxidative chemistries also emerge in hospital acquired acute kidney injury caused by: − Ischemia reperfusion injury − Contrast dye induced nephro

  10. Slide 10: Ischemia-Reperfusion (I/R-AKI)

    Ischemia-Reperfusion (I/R-AKI) Tubules (proximal or distal ) Tubular epithelium (damaged) Capillaries where blood is circulating Interstitial between capillaries and tubules where usually interstitial fibrosis is formed Tubular epithelium (normal) Endothelial cells Different type of blood cells 10

  11. Slide 11: Oral Pyridorin – Significant Market Potential

    Oral Pyridorin – Significant Market Potential DN patients progress from high risk, to early stage (microalbuminuria), to overt nephropathy (macroalbuminuria), to end stage renal disease (ESRD) and dialysis 19 M diagnosed diabetics in the US, of which 33% (6.3 M) exhibit kidney disease  2.8 M macroa

  12. Slide 12: Phase 2a PYR-205/207

    NephroGenex 6 Month Phase 2a PYR-205/207 Pyridorin at a 250 mg bid dose is well tolerated and slows the rate of SCr increase in moderate to advanced disease patients Two multi-center, randomized, double-blind, placebo-controlled trials  Number of centers: 20 (U.S., Belgium, United Kingdom, Canada,

  13. Slide 13: Phase 2b PYR-210

    NephroGenex 12 Month Phase 2b PYR-210 Established SOC patients approved by FDA for Phase 3 Patients on established (or stable) standard of care (SOC) at screening exhibit a highly significant dose-dependent treatment effect in the FDA approvable RENAAL patient population Patients not on SOC at scree

  14. Slide 14: Phase 1 and 2 Safety Trials

    NephroGenex Phase 2 Safety Trials Pyridorin was well tolerated, had a benign safety profile, and slowed the rate of SCr increase in patients on stable SOC at screening  No maximum dose tolerability found in animals & healthy humans  There were no differences between groups in SAEs, mortality or ES

  15. Slide 15: PIONEER Pyridorin Phase 3 Trial Protocol

    PIONEER Pyridorin Phase 3 Trials Protocol Objective: Evaluate safety and efficacy of Pyridorin at a 300 mg twice daily dose compared to placebo to reduce the rate of renal disease progression due to type 2 diabetes mellitus Patient Population  Baseline SCr from 1.3 and less than 3.0 mg/dL (eGFR > 2

  16. Slide 16: PIONEER Trial Interim Analysis

    PIONEER Trial Interim Analysis Interim analysis expected first half of 2016 The Company expects to conduct an interim analysis after all 600 patients have received at least 6 months of study drug The DSMB will be reviewing for safety The interim analysis will be event-based and conducted by an indep

  17. Slide 17: PYRIDORIN Timeline

    PYRIDORIN Timeline Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Secured CRO (Collaborative Study Group & Medpace) Enrolled first patient in PIONEER (PYR-311) pivotal Phase 3 trial (June 2014) Publication on new end point (Nov 2014) Posters presentations at American Society of Nephrology (Nov 2014) Successful

  18. Slide 18: Exclusivity: Patents and New Chemical Entity

    Exclusivity Patents and New Chemical Entity (NCE) No composition of matter claim since this molecule already exists in the human body in microscopic quantities U.S.  Method of use (including patient population and dosage) patent December 2028 (with anticipated patent term extension)  Method of man

  19. Slide 19: Corporate Summary

    Corporate Summary Experienced management team focused on clinical success Diabetic nephropathy represents a large and growing unmet need Oral Pyridorin Pivotal Phase 3 program in DN initiated  Demonstrated benign safety profile in Phase 1 and Phase 2 a & b studies  Phase 3 program is studying the

  20. Slide 20: Appendix

    Appendix i) NephroGenex

  21. Slide 21: PIONEER Pyridorin Phase 3 Trial Protocol: Endpoints

    PIONEER Pyridorin Phase 3 Trials Protocol Primary end points: Evaluate Pyridorin 300 mg twice daily (BID) efficacy compared to placebo in reducing the rate of progression of renal disease due to type 2 diabetes mellitus. With time to the composite endpoint consisting of the earliest event amongst: 

  22. Slide 22: Pyridorin Safety Profile: PYR-210

    Pyridorin Safety Profile: PYR-210 Most Reported Adverse Events Most Reported Serious Adverse Events Pyridorin has a benign safety profile with the possible exception of a small increase in diarrhea and constipation with the higher dose of 300 mg bid  No meaningful differences between groups in AEs

  23. Slide 23: Pyridorin Phase 2a Program PYR-206

    Pyridorin Phase 2a Program PYR-206 Multi-center, randomized, double-blind, placebo-controlled trial  Number of centers: 46  Location of centers: U.S.  Dose: 50mg BID x 24 weeks  Study objectives: assess safety, tolerability and biological activity Diabetic patients with DN due to type 1 or type

  24. Slide 24: Clinical Results PYR-206

    Clinical Results PYR-206 Mild to Moderate Diabetic Nephropathy – Dose 50 mg BID Pyridorin at a 50 mg bid dose is well tolerated and slows the rate of SCr increase in mild to moderate disease patients Note: Virtually all patients on standard of care at screening – ACEI/ARB therapy and blood pressure

  25. Slide 25: Clinical Results PYR-205/207

    Clinical Results PYR-205/207 Moderate to Advanced Diabetic Nephropathy – Dose 250 mg bid Pyridorin at a 250 mg bid dose is well tolerated and slows the rate of SCr increase in mild to moderate disease patients Note: Virtually all patients on standard of care at screening – ACEI/ARB therapy and blood

  26. Slide 26: Clinical Results PYR-210

    Clinical Results PYR-210 Type 2 Diabetic Nephropathy Patients With and Without SOC 1at screening – 300 & 150 mg bid Patients on SOC at screening exhibit a highly significant dose-dependent treatment effect in the FDA approvable RENAAL patient population Patients not on SOC at screening exhibit highe

  27. Slide 27: Urinary TGFb Analysis

    NephroGenex Phase 2 Urinary TGFb Analysis Placebo Pyridorin PYR-206 1 +15.9 pg/mg Baseline 36.7 pg/mg N=51 -9.8 pg/mg Baseline 38.6 pg/mg N=51 PYR-205/207 2 +15.3 pg/mg Baseline 27.8 pg/mg N=21 -5.2 pg/mg Baseline 34.7 pg/mg N=42 TGFb promotes renal fibrosis. As diabetic nephropathy progresses, urin

  28. Slide 28: Serum Creatinine and eGFR Definitions

    Definition  Serum Creatinine (SCr) – the level of creatinine, a by-product of muscle metabolism, circulating in the blood  Estimated Glomerular Filtration Rate (eGFR) – an estimate of the rate that the glomerulus filters blood based on circulating SCr levels corrected for age, sex, and race Compar

  29. Slide 29: Competitive Environment

    NephroGenex Competitive Environment 29 Company Agent Phase Program Status NephroGenex Inhibitor of pathogenic oxidative chemistries and AGE formation 3 Active AbbVie Endothelin receptor antagonist 3 Active Janssen INVOKANA SGLT2 Inhibitor 3 Active Pfizer Chemokine CCR2/5 Receptor Antagonist Phosphod

  30. Slide 30: Recent Phase 3 M&A Transactions

    Date Development Stage Therapeutic Area Acquirer Acquired Transaction Market Value 7/01/2014 Phase 3 CNS Paratek Pharma Transcept Pharma $289.9 M 12/19/2014 Phase 3 Cardiovascular Jazz Pharma Gentium $860.4 M 7/30/2014 Phase 3 Infectious Diseases Cubist Pharma Optimer Pharma $674.0 M 5/28/2013 Phase

NephroGenex — Investor Presentation (February 2015) on 6ix